IMPACT OF RETINAL ISCHEMIA ON FUNCTIONAL AND ANATOMICAL OUTCOMES AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN PATIENTS WITH RETINAL VEIN OCCLUSION
IMPACT OF RETINAL ISCHEMIA ON FUNCTIONAL AND ANATOMICAL OUTCOMES AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN PATIENTS WITH RETINAL VEIN OCCLUSION
复制标题
DOI：
10.1097/iae.0000000000002571
复制
发表时间：
2020-06-01
影响因子：
3.3
通讯作者：
Lois, Noemi
中科院分区：
文献类型：
--
作者：
Khayat, Meiaad;Wright, David M.;Lois, Noemi
目的：比较视网膜静脉阻塞（RVO）分为缺血型或非缺血型对抗血管内皮生长因子治疗后结局的影响。研究方法：对2014年7月1日至2015年12月31日期间在贝尔法斯特健康和社会护理信托基金评价的连续RVO患者进行回顾性审查。使用回归模型比较缺血性和非缺血性患眼的结局，包括12个月时增加>= 10和>= 15个字母，最佳矫正视力从基线到12个月的平均变化，12个月时黄斑水肿的消退，以及抗血管内皮生长因子治疗后新生血管并发症和视网膜前膜的发生。结果：115例（117眼）中央型RVO 58眼，分支型RVO 59眼。缺血性分支RVO的患眼在12个月时比非缺血性分支RVO的患眼增加>= 10和>= 15个字母的比例更大（分别为P = 0.005和P = 0.016）。缺血性和非缺血性中央RVO之间的视力结果无统计学显著差异。视网膜静脉阻塞分类与治疗后的解剖结果无关。结论：研究结果支持使用抗血管内皮生长因子在缺血性和非缺血性形式的RVO。
Purpose: To compare the impact of the classification of retinal vein occlusion (RVO) into ischemic or nonischemic forms on outcomes after anti-vascular endothelial growth factor therapy. Methods: Retrospective review of consecutive patients with RVO evaluated at the Belfast Health and Social Care Trust between July 1, 2014, and December 31, 2015. Outcomes, including gain of >= 10 and >= 15 letters at 12 months, mean change in best-corrected visual acuity from baseline to 12 months, resolution of macular edema at 12 months, and development of neovascular complications and epiretinal membrane after anti-vascular endothelial growth factor therapy, were compared between ischemic and nonischemic eyes using regression models. Results: One hundred and seventeen eyes (115 patients), 58 with central RVO and 59 with branch RVO, were included. A greater proportion of eyes with ischemic branch RVO gained >= 10 and >= 15 letters at 12 months than those with nonischemic branch RVO (P = 0.005 and P = 0.016, respectively). No statistically significant differences in visual outcomes were observed between ischemic and nonischemic central RVO. Retinal vein occlusion classification was not associated with anatomical outcomes after treatment. Conclusion: Findings support the use of anti-vascular endothelial growth factors in ischemic and nonischemic forms of RVO.